Mindmed initiates phase 2a lsd trial for the treatment of adult adhd

- enrolling patients in proof-of-concept exploratory trial conducted in collaboration with the university hospital basel in switzerland and maastricht university in the netherlands – -trial led by dr. matthias liechti and dr. kim kuypers, pioneers and leading global experts in the psychedelic landscape – new york, dec. 17, 2021 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (de: mmq) (the "company"), a leading biotech company developing psychedelic-inspired therapies, today announced the initiation of phase 2a proof-of-concept (poc) trial of lysergic acid diethylamide (lsd) in adult patients with attention deficit hyperactivity disorder (adhd). the first site has been activated and patient enrollment is expected to start imminently.
MNMD Ratings Summary
MNMD Quant Ranking